Consulting agreement with Dr. Dolsten for research and development services, effective March 3, 2025, terminated December 31, 2025; compensation of cash paid in monthly installments and RSUs that cliff vested December 31, 2025.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Gaurav Shah
Also a director
Chief Executive Officer and Director
|
51 | Not stated | Not stated | $3,510,241 | |
|
Martin Wilson
General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer
|
49 | Not stated | 2021 | $3,397,880 | |
|
Christopher Stevens
Chief Operating Officer
|
46 |
Since 2025
1 year
|
2025 | $3,555,467 | |
|
Syed Rizvi
Chief Medical Officer
|
59 |
Since 2025
1 year
|
2025 | Not reported | |
|
Jonathan Schwartz
Chief Science & Gene Therapy Officer
|
62 | Not stated | 2016 | Not reported | |
|
Joseph Manhede
Principal Accounting Officer
Title from the Form 8-K dated Jul 8, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Sarbani Chaudhuri
See Remarks
Title from the Form 4 dated Nov 9, 2026
|
51 | Not stated | 2025 | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Consulting agreement with Dr. Dolsten for research and development services, effective March 3, 2025, terminated December 31, 2025; compensation of cash paid in monthly installments and RSUs that cliff vested December 31, 2025.
Loading...